Pfizer Inc. (PFE)
Pfizer, Innovent GLP-1 drugs pass China insurance preliminary review
Pfizer's GLP-1 drug Ecnoglutide and Innovent Biologics' mazdutide injection have passed a preliminary review to be potentially included in China's basic medical insurance drug catalogue, a a list published by the National Healthcare Security Administration showed on Monday.
Opinion: Pfizer Is a Fantastic Dividend Stock for Income Investors to Buy Right Now
Pfizer is one of the world's largest drug companies. It has a long history of navigating the industry's ups and downs.
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Pfizer (PFE) Falls More Steeply Than Broader Market: What Investors Need to Know
In the most recent trading session, Pfizer (PFE) closed at $24.04, indicating a -2.75% shift from the previous trading day.
Nike names former Pfizer CFO David Denton as finance chief
Nike Inc (NYSE:NKE, XETRA:NKE) has announced that David Denton will join the company as executive vice president and chief financial officer effective August 17, succeeding Matthew Friend, who will remain with the company through September 4 to support the transition. According to the company, Denton will lead Nike's global finance organization and work alongside president and CEO Elliott Hill and the senior leadership team on capital allocation, financial discipline and long-term growth initiatives.
Nike Names Pfizer's Denton as Next CFO
David Denton's appointment, effective Aug. 17, comes as the company struggles to execute its turnaround.
Forget Novo Nordisk. Pfizer's Obesity Pipeline Is Coming, and It Pays You 6.8% While You Wait
Everyone is still arguing about Novo Nordisk (NYSE:NVO | NVO Price Prediction), the Danish obesity juggernaut whose
China outpacing Europe in drug innovation and development, Pfizer executive says
China has pulled ahead of Europe in pharmaceutical innovation and drug development, a senior Pfizer executive said on Tuesday.
Pfizer's Mixed Phase III Data for Sigvotatug Vedotin in NSCLC
PFE's phase III NSCLC study misses a key survival goal overall, but a large subgroup shows favorable survival trends vs docetaxel.
Eli Lilly vs Pfizer: One Owns the Obesity Market Today, The Other Paid to Compete Tomorrow
Eli Lilly (NYSE: LLY | LLY Price Prediction) and Pfizer (NYSE: PFE) just delivered Q1 2026 results that read like two different chapters of the same drug industry.
PFE Stock Slides Following CFO Exit, 2026 Guidance Reaffirmed
Pfizer shares fall after CFO Dave Denton announces his exit, though the company reaffirms 2026 guidance and maintains its strategic outlook.
Pfizer (PFE) Stock Declines While Market Improves: Some Information for Investors
Pfizer (PFE) reached $25.22 at the closing of the latest trading day, reflecting a -2.72% change compared to its last close.
